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Adeno-associated virus (AAV) vectors have emerged
as a gene-delivery platform with demonstrated
safety and efficacy in a handful of clinical trials for
monogenic disorders. However, limitations of the
current generation vectors often prevent broader
application of AAV gene therapy. Efforts to engineer
AAV vectors have been hampered by a limited under-
standing of the structure-function relationship of
the complex multimeric icosahedral architecture
of the particle. To develop additional reagents perti-
nent to further our insight into AAVs, we inferred
evolutionary intermediates of the viral capsid using
ancestral sequence reconstruction. In-silico-derived
sequences were synthesized de novo and character-
ized for biological properties relevant to clinical ap-
plications. This effort led to the generation of nine
functional putative ancestral AAVs and the identifica-
tion of Anc80, the predicted ancestor of the widely
studied AAV serotypes 1, 2, 8, and 9, as a highly
potent in vivo gene therapy vector for targeting liver,
muscle, and retina.
INTRODUCTION
Extensive preclinical studies have established a favorable safety
profile for adeno-associated virus (AAV) vectors. In addition, AAV
vectors have enabled demonstration of in vivo gene therapy ef-
ficacy in animal models of disease with etiologies ranging from
inherited to infectious to common complex (Hastie and Samul-
ski, 2015; Schnepp and Johnson, 2014). Furthermore, recent
early-stage AAV clinical trials have led to the first demonstrations
of clinical benefit in two forms of inherited blindness with AAV2
(Bainbridge et al., 2008; Jacobson et al., 2012; MacLaren
et al., 2014; Maguire et al., 2008) and hemophilia B with AAV8
(Nathwani et al., 2011). One treatment based on AAV1 has
been awarded a drug license by European regulators (Bryant
et al., 2013). Based on these data, AAVs have been proposed
as a platform technology for therapeutic in vivo gene delivery.1056 Cell Reports 12, 1056–1068, August 11, 2015 ª2015 The AuthoAAV is a 25-nm non-enveloped icosahedral capsid virus car-
rying a 4.7-kb single-stranded DNA genome flanked by inverted
terminal repeats (ITRs). AAV classifies as a Dependoparvovirus
genus within the Parvoviridae family. Its genome comprises
genes encoding for replication (Rep), structural capsid (Cap),
and assembly (AAP) proteins. AAV is a helper-dependent virus,
requiring the heterologous cofactors to complete a replicative
cycle that an adenovirus or herpesvirus can provide in the
context of a co-infection. Replication-deficient AAV can be
generated by eliminating all viral coding sequence in cis and
providing those in trans during vector production. Particles
generated in this manner can encode any type of transgene
cassette that does not exceed the size of the genome of the
wild-type virus (4.7 kb) and enable gene transfer in vitro and
in vivo to multiple cell and tissue targets (Knipe and Howley,
2013).
The AAV particle is composed of three C-terminally overlap-
ping Cap proteins named VP1, 2, and 3. VP3, the smallest mem-
ber of these structural proteins, is necessary and sufficient for
full capsid assembly through multimerization. VP1, required for
particle infectivity, and VP2, reported to be redundant structur-
ally or functionally, are embedded in the wild-type T = 1 viral
architecture at a VP1:2:3 ratio of 1:1:10. A total of 60 VP
monomers assemble into an icosahedral capsomer along 2-,
3-, and 5-fold axes of symmetry (Knipe and Howley, 2013). Every
monomer within the 60-mer structure interfaces with seven
neighboring capsid monomers. High-resolution crystallography
studies identify a conserved core structure composed of an
eight-stranded b-barrel motif and the aA helix as well as nine sur-
face-exposed domains (VR-I to -IX), which can vary between the
known primate AAV serotypes (DiMattia et al., 2012; Xie et al.,
2002).
The structural diversity of natural AAVs is therefore largely
contained within the nine surface regions of the capsid, which
functionally results in divergent receptor-binding properties,
post-entry trafficking, host response, and gene transfer effi-
ciency to various cell and tissue targets. Structural determinants
for many of these properties have largely remained elusive, with
a few notable exceptions: receptor-binding motifs for certain se-
rotypes (Bell et al., 2012; Kern et al., 2003;Wu et al., 2000), phos-
pholipase activity and nuclear localization activity on VP1,2
unique domains (Girod et al., 2002; Grieger et al., 2006), a limitedrs
number of docking sites for monoclonal antibodies (DiMattia
et al., 2012), a motif enhancing T cell immunogenicity (Vanden-
berghe et al., 2006), and a select number major histocompatibil-
ity complex I (MHCI)-restricted T cell epitopes (Mingozzi et al.,
2007) have previously been mapped.
In an era of active clinical translation in AAV gene therapy,
there is a desire to better understand the structure-function rela-
tionship of AAVs within the constraints of the particle architec-
ture in order to further model and modulate the pharmacology
of this new class of drugs to improve transduction efficiency
and specificity, alter tropism, and reduce immunogenicity. To
enable mechanistic studies, map structural determinants of
these phenotypes, and facilitate future rational AAV design
aimed to mitigate the clinical limitations of the current technol-
ogy, both reverse and forward genetic studies on AAVs have
been pursued. A wealth of naturally occurring AAV variants
have been studied extensively and yielded large descriptive da-
tasets (Gao et al., 2003, 2004, 2005). Forward genetic studies
have resulted in important findings (Adachi et al., 2014; Asuri
et al., 2012; Bartel et al., 2012; Dalkara et al., 2013; Huttner
et al., 2003; Koerber et al., 2008; Li et al., 2008; Lisowski et al.,
2014; Maheshri et al., 2006; Mays et al., 2013; Perabo et al.,
2003; Shen et al., 2007; Wu et al., 2000) but often remain con-
strained by the limited tolerance for structural change of the rigid
architecture of AAVs (Adachi et al., 2014; Huttner et al., 2003; Lo-
chrie et al., 2006; Mays et al., 2013; Shen et al., 2007; Vanden-
berghe et al., 2009; Wu et al., 2000). Rational AAV design has
therefore been difficult in structurally isolating and modulating
vector phenotypes while retaining integrity and the desirable as-
pects of its innate function and biology of the particle.
Here, we hypothesized that the divergent AAV phenotypes
and structural determinants underlying its biology and pharma-
cology could be mapped by recreating the evolutionary lineage
of this virus. Under selective pressure, evolutionary intermedi-
ates along the lineage undergo phenotypic modulation while
balancing these changes with the retention of structural and
functional integrity that are expected to highlight evolutionary
couplings and epistatic interactions. We used ancestral
sequence reconstruction (ASR) methods to predict the amino
acid sequence of putative ancestral AAV capsid monomers us-
ing maximum likelihood (ML) methods (Finnigan et al., 2012).
This led to the reconstruction of nine nodes along the phylogeny
of common ancestry of most of the AAV serotypes under clinical
testing or consideration (AAV1–3 and 6–9). Through de novo
gene synthesis of these reverse-translated ancestral capsid pro-
teins, we demonstrate assembly and infectivity of members
across this AAV lineage. The most distal presumed ancestor of
the lineage, Anc80, was extensively characterized for its perfor-
mance as a gene therapy vector and was demonstrated to be a
potent broadly applicable vehicle for gene therapy with unique
properties.
RESULTS
In Silico Ancestral Sequence Reconstruction of AAV
Capsid Protein
In lieu of attempting to isolate an intact ancestral viral sequence
from proviral DNA or archeological samples, contemporary AAVCellsequence data were integrated through phylogenetic analysis
and ML-ASR in order to infer the putative ancestral amino acid
sequence for the AAV Cap. A total of 75 sequences of AAV sero-
type isolates and variants from previous biomining efforts (Gao
et al., 2003, 2004) led to a robust AAV Cap phylogeny generated
with PHYML (Guindon et al., 2010) with AAV5 as an outgroup.
Only full-length AAV capsids were included in this analysis that
were (1) naturally occurring in primate populations, (2) previously
demonstrated to assemble and infect efficiently, and (3) not
known to have arisen through recombination events in its natural
history, as traditional phylogenic analysis and ASR do not ac-
count for horizontal evolutionary events. The dendrogram in Fig-
ure 1 models the evolutionary path of AAVs with early speciation
of AAV4 and 5 serotypes, parallel to a single node, namedAnc80,
from which most known contemporary AAVs evolved. These
serotypes include AAV1, 2, 8, and 9, currently in human gene
therapy trials. Nodes in this phylogeny were named Anc and
numbered sequentially. To validate our approach, the Anc80
node was developed into a recombinant virus for possible use
as a gene therapy vector (Figure 1).
Anc80 was chosen in part because the reconstruction of this
node was highly informed by the abundance of naturally occur-
ring and clinically relevant AAV descendants. Furthermore,
Anc80 is embedded in the phylogeny of the Dependoparvoviri-
daewith known helper-dependent primate AAVs that arose prior
to Anc80’s speciation (Figure 1), making it more likely that the
ancestrally reconstructed particle retains the basic properties
shared within this family. UsingMLmethods, a protein sequence
prediction was derived for Anc80 based on calculated posterior
probabilities for each residue in a particular position. In order to
account for the uncertainty in selecting the appropriate amino
acid in each position, we aimed at generating all possible
sequence permutations for positions with individual-amino-
acid posterior probabilities with p R 0.3. A representation of
this library, Anc80Lib, is illustrated in Figure 2A in a part-struc-
tural alignment with an AAV2 and AAV8 reference capsid
sequence. Practically, this led to a probabilistic sequence space
composed out of sequences for which most of the 736 Anc80
capsid amino acid positions were fixed due to the high certainty
in those positions by the ML-ASR, while for 11 positions, two
amino acid optionswere provided, resulting in a sequence space
encompassing 211 = 2,048 permutations.
Structural and sequence alignment of Anc80Lib with extant
AAVs and their X-ray crystallography data highlight significant
divergence from currently known circulating AAVs. The closest
homolog as determined via BLAST search is rh.10, a rhesus ma-
caque isolate within clade E of the primate Dependoparvoviri-
dae, which differs from Anc80Lib by minimally 7.8%, which
accounts for 58 divergent amino acid positions (Figure 2B).
AAV8 and AAV2 differ 8.7% and 12.0%, respectively, and those
65–89 variable sites are distributed unevenly over the entire VP1
protein, including the VP1 and 2 unique domains (Figures 2A and
2B). Divergence is highest in the hypervariable domains I, IV, VII,
and VIII, both in terms of sequence as well as based on structural
modeling of Anc80Lib clones in overlay with AAV2 and eight
monomeric structures (Figures 2A and 2C). Mapping of the var-
iable Anc80 residues onto trimeric X-ray crystallography models
of AAV2 and AAV8 in Figure 2D highlight most changes to beReports 12, 1056–1068, August 11, 2015 ª2015 The Authors 1057
Figure 1. Phylogeny and ASR of AAV Evolu-
tionary Lineage
Maximum-likelihood phylogeny relating 75 iso-
lates of AAV. Red circles represent evolutionary
intermediates reconstructed through ASR. Blue
circle represents library of probabilistic sequence
space around Anc80. Subclades are collapsed for
clarity. Full phylogeny and sequence alignment is
presented in Figures S2 and S3.concentrated on the external surface of the virion, particularly on
peak and flanks of the protrusions around the 3-fold axis of
symmetry. However, a significant number of variable residues
were also noted on the surface-exposed domains outside of
the 3-fold axis in addition to a smaller number of variations on
the internal surface of the particle and on regions of Cap that
are not resolved in the X-ray structures.
Anc80 Synthesis and Basic Characterization
Anc80Lib protein sequences were subsequently reverse trans-
lated and generated by gene synthesis in pooled library format.
Capsid genes were cloned into an AAV packaging plasmid en-
coding AAV2 Rep into pAnc80Lib following which the library
was deconvoluted clonally. Individual clones (named pAnc80LX,
with X a consecutive number) were evaluated in isolation to avoid
potentially interfering competitive interactions in a minimally
divergent library population. A portion of individual Anc80 clones
were Sanger sequenced, verifying integrity and complexity re-
quirements. Clonal Anc80 plasmids were co-transfected with a
DF6 adenoviral helper plasmid, an expression construct for
AAP derived from AAV2 (AAP2), and ITR flanked expression
construct encoding luciferase. A total of 776 library clones
were produced and inoculated at equal volume of producer
cell lysate on HEK293 cells in a semi-high-throughput assay
aiming to assess combined particle assembly and transduction
efficiency. Approximately 50%of the Anc80 clones led to detect-1058 Cell Reports 12, 1056–1068, August 11, 2015 ª2015 The Authorsable signal over background in this
rudimentary screening assay. Several
lead candidates with highest luciferase
signal progressed to sequencing confir-
mation and titration for DNase-I-resistant
genome-containing particles (GCs) and
infectivity on HEK293 cells. Based on
these results Anc80L65, the 65th An-
c80Lib clone that was evaluated, was
selected for further characterization.
Anc80L65 vector yields from cell lysate
are between 82% and 167% of AAV2
yields, yet they were depressed com-
pared to the high-yielding AAV8
(3%–5% relative AAV8 yields). In vitro
infectivity on HEK293 is inferior to AAV2
but superior to AAV8 on a particle-per-
cell basis.
Anc80L65 vector preparations were
produced and purified on an iodixanol
gradient at scale following traditional pro-tocols and subjected to a variety of biochemical, biophysical,
and structural analyses. Particles within a purified preparation
of Anc80L65 were visualized under negative staining by electron
microscopy (EM) (Figure 3A). Anc80L65 virions present as rela-
tively uniform hexagonally shaped particles with a diameter of
20–25 nm, not unlike other AAV capsomers. Denatured parti-
cles resolved under SDS electrophoresis into three bands of
60, 72, and 90 kDa, in a ratio of 1:1:10 corresponding to the
VP1–3 proteins from AAV2 and AAV8 particles (Figure 3B).
Analytical ultracentrifugation (AUC) allowed us to determine the
sedimentation coefficient of genome containing Anc80L65 at
88.9 S, slightly increased from AAV8’s (85.9 S) (Figure 3C). This
analysis permitted us further to determine the relative abun-
dance of empty or lower-density assembled particles, presumed
to be lacking a vector genome, as well as overall purity. One
concern was that inaccurate modeling of the ancestral capsid
sequence may have resulted in a structure deficient in its ability
to package genomes and would result in a skewed empty versus
full ratio in Anc80L65 preparations. Results indicated 16%
empty versus 85% full particles in our preparation, in line with
observations with AAV8 (Figure 3C). Additionally, we hypothe-
sized particle stability may be reduced due to suboptimal
modeling of the ancestral capsid composition. We subjected
the particle to heat-stability assays, which determined (against
our expectations) that Anc80L65 was 15C –30Cmore heat sta-
ble than AAV2 and AAV8 (Figure 3D).
Figure 2. Sequence and Structural Analysis of Anc80 Vectors
(A) Sequence alignment of Anc80, AAV2, and AAV8 VP3 proteins. A structural alignment derived from the crystal structures of AAV2 (PDB: 1LP3) and AAV8 (PDB:
2QA0) VP3 and the predicted structure of Anc80L65 VP3 was generated with UCSF Chimera (Pettersen et al., 2004) and is represented in black print. The blue
region is a non-structural alignment of the VP1/VP2 domains of AAV2, AAV8, and Anc80 (Notredame et al., 2000). Ambiguous residues in Anc80Lib are in red print
with the lower position corresponding to Anc80L65 residues. b strands and a helices are represented in green and yellow, respectively. The positions of the nine b
strands forming the AAV antiparallel b-barrel are depicted with plain arrows whereas the position of the conserved core a-helix is depicted with a dotted arrow.
The approximate positions of variable regions (VR) I-IX are represented by the roman numerals above the sequence alignment.
(B) AAV Cap sequence divergence matrix. Above the diagonal, the table shows the percent sequence divergence from selected AAV serotypes, as well as rh.10,
the most homologous VP1 sequence as determined by BLAST. Below the diagonal, the number of amino acid differences per position is presented.
(C) Superimposition of AAV2 and AAV8 VP3 crystal structures with Anc80L65 VP3 predicted structure. The color code depicts the amino acid conservation
among the three aligned sequences of (A) (red, highest conservation; blue, lowest conservation). Variables regions I–IX andC/M termini are indicated in black. The
approximate positions of the 2-, 3- and 5-fold axes are represented by the black ellipse, triangle, and pentagon, respectively.
(D) Structural mapping of amino acid changes as compared to AAV2 (left) and AAV8 (right) on VP1 trimer visualizing the external (top) and internal (bottom) of the
virion. Colored residues are divergent in Anc80. Red residues are ambiguous via ASR and therefore dimorphic in Anc80Lib.In Vivo Gene Transfer and Transduction of Anc80L65 in
a Murine Model
Next, we evaluated the ability of Anc80L65 packaged trans-
genes to be delivered and expressed from three clinically rele-
vant target tissues and routes of administration (ROA) in the
C57Bl/6 mouse: (1) liver following a systemic injection, (2) skel-
etal muscle following direct intramuscular injection, and (3) a
subretinal injection for outer retina targeting. Large-scale prepa-
rations of Anc80L65 were produced along with AAV2 and AAV8
controls with reporter genes andwere injected at equal doses for
liver-, muscle-, and retina-directed gene transfer in adult male
C57Bl/6 mice. Expression (presented in Figure 4) was monitored
qualitatively (EGFP and/or LacZ) for all three target tissues and
quantitatively via serum ELISA measurement of the secretedCellhA1AT (liver) at various time points. Liver-directed gene transfer
was observed to be robust via two routes of administration and
transgenes (Figures 4A–4C). Analogously to AAV8, hepatocytes
were targeted efficiently as observed by LacZ and GFP staining
surpassing the limited permissivity described for AAV2 (Nakai
et al., 2002, 2005). Quantitatively, Anc80 demonstrated similar
efficiency of transduction to AAV8 by intracellular reporter and
a secreted serum protein transgene product. Dose-ranging
studies demonstrated a linearity of gene transfer with dose
above 1010 GCs/mouse but a threshold below which linearity
was not maintained for hA1AT (and less obvious by EGFP) (Fig-
ures 4B and 4C). A biodistribution study at the high dose of 5 3
1011 GCs/mouse was conducted at days 7 and 28 postinjection
to evaluate tissue distribution of vector genomes in liver, heart,Reports 12, 1056–1068, August 11, 2015 ª2015 The Authors 1059
Figure 3. Biophysical and Biochemical Characterization of Anc80L65
(A) Negative staining transmission electron microscopy (TEM) of Anc80L65 particles.
(B) Anc80L65 viral protein composition by SDS-PAGE. Purified AAV preparations were analyzed by SDS-PAGE, demonstrating similar incorporation levels of the
monomers VP1–3.
(C) Anc80L65 sedimentation and empty:full particle profile. Sedimentation coefficient distributions were derived from the refractive index optical measurement
systems during analytical ultracentrifugation of AAV8 and Anc80L65 iodixanol purified preparations.
(D) Anc80L65 thermostability. SDS page thermostability assessment of an AAV particle illustrates dissociation into monomers for AAV2 and 8 at temperatures
below 70C for AAV2 and 8 but requiring 95C melting temperatures for Anc80L65.spleen, kidney, and lung of Anc80L65 alongside AAV8 as a con-
trol (Table S1). Results show similar ranges of gene transfer of
Anc80 to AAV8 in the tissues tested, with moderate increases
for Anc80L65 in spleen, heart, and lung. Via direct skeletal intra-
muscular injection, Anc80 efficiently targeted myofibers prox-
imal to the injection site and longitudinally extending across
the fiber (Figures 4A and S1). Retinal transduction after subreti-
nal injection is efficient in targeting the retina pigment epithelium
(RPE), as was the case in AAV2 and AAV8 as previously noted
(Auricchio et al., 2001). Photoreceptor targeting, a more difficult
cell target, as is documented for AAV2, was observed with AAV8
and Anc80L65 (Allocca et al., 2007). While both AAV8 and
Anc80L65 targeted the majority of photoreceptor cells, trans-
duction with Anc80L65 leads consistently to higher expression
levels per cell. A limited number of cells in the inner retina were
also observed to be GFP positive by Anc80L65 transduction
(Figure 4A).
Anc80L65 Gene Transfer and Expression in Non-human
Primate Liver
Given the robust hepatotropism of Anc80L65 in mice, we aimed
at evaluating gene transfer of Anc80L65 in a large animal model.
Six female rhesus macaques that were previously enrolled in
prior studies unrelated to AAV were injected via saphenous
vein with either AAV8 or Anc80L65 at a clinically relevant dose
of 1012 GCs/kg (Table S2). AAVs expressing the rhesus cDNA
for the b subunit of the chorionic gonadotropin (rhCG), a trans-
gene product that the animals are tolarized for in order to avoid
a non-self transgene immune response, was used as transgene.1060 Cell Reports 12, 1056–1068, August 11, 2015 ª2015 The AuthoAnimals were selected based on neutralizing antibody (NAB) to
AAV8 and Anc80L65 with serum levels prior to injection below
1/4 titer. Gene transfer was assessed by TaqMan qPCR for vg
of total liver DNA (caudal lobe) 70–71 days following injection
(Figure 4D). Surprisingly, two out of three control AAV8-injected
animals had underwhelming gene transfer (<0.1 vg/dg), likely
due to low-level NAB at the time of injection undetectable by
standard NAB assays as reported in previous studies. One
AAV8 animal, presumably with no or minimal NAB to AAV8,
demonstrated gene transfer levels for liver within the expected
range of 0.81 vg/dg. Anc80L65 gene transfer was efficient,
with three animals yielding hepatic transgene copy numbers
ranging from 0.73 to 3.56 vg/dg. Liver expression wasmonitored
via qRT-PCR (Figure 4E); Anc80L65 led to expression superior to
the AAV8 and achieved rhCG transcript levels between 13% and
26% of total GAPDH mRNA amounts in all liver lobes.
Safety, Immunology, and Toxicology of Anc80L65
The consideration to use any efficient gene-delivery vector sys-
tem for therapeutic application requires extensive evaluation of
its safety for clinical use. In addition, the use of a novel agent
that may approximate an ancestral state of aDependoparvovirus
may further raise those concerns. Here, in a non-formal preclin-
ical setting, we examined several important aspects that may
limit Anc80L65 from a safety perspective. Animal expression
studies (Figure 4) were monitored for obvious signs of toxicity
during the in-life phase of the study and for target-tissue-specific
toxicity. No notable adversity was found to be associated with
the vector injection. In brief, vector administration followingrs
Figure 4. Anc80L65 In Vivo Transduction Biology
(A)Mouse liver transduction and lacZ transgene expression comparison of AAV2, AAV8, and Anc80L65.TBG.nLacZ in liver 28 days after intraperitoneal delivery at
a dose of 3.93 1010 GCs (C57Bl/6, n = 3) (top). AAV2, AAV8, and Anc80L65muscle tropism inmouse 28 days following an intramuscular delivery at a dose of 1010
GCs to the rear-right thigh (gastrocnemius) (n = 5) (middle). See also Figure S1. Comparison of EGFP transgene expression among AAV2, AAV8, and Anc80L65 in
the murine retina after subretinal delivery at a dose of 2 3 109 GCs (bottom). AAV2 shows high affinity for RPE cells, while both RPE and photoreceptors are
targeted using AAV8 and Anc80L65 vectors, with Anc80L65 showing higher transduction efficiency compared to AAV2 and 8 (C57Bl/6, n = 4 eyes).
(B) Qualitative dose-response hepatic EGFP-expression analysis following dosing of 1011 (top), 1010 (middle), and 109 (bottom) GCs comparing AAV8 and
Anc80L65 by retro-orbital intravenous injection in mouse. Both AAV8 and Anc80L65 lead to comparable EGFP expression at equal dose throughout the dose
ranging (C57Bl/6, n = 3).
(C) Quantitative AAV dose-response analysismeasuringmouse serum levels of recombinant human alpha 1-antitrypsin (hA1AT) transgene expression from AAV8
(black symbols: square, 1011 GCs; circle, 1010 GCs; and four-square, 109 GCs) and Anc80L65 (gray symbols: diamond, 1011 GCs; square, 1010 GCs; and triangle,
109 GCs) (C57Bl/6, n = 5). See also Tables S1 and S3–S5.
(D) Rhesusmacaque liver gene transfer of AAV8 and Anc80L65 expressing Rhesus chorionic-gonadotropin (rhCG) following saphenous vein injection of a dose of
1 3 1012 GCs/kg. Genomic DNA was harvested from macaque liver-lobes and viral genome (vg) per diploid genome (dpg) was measured by qPCR assay. One
AAV8 animal and all three Anc80L65 animals successfully received1–3 vg per diploid cell of the caudal liver lobe, while 2 AAV8 animals likely had low-level NAB
resulting in vector neutralization and limited liver gene transfer. Error bars represent SD. See also Tables S2, S6, and S7.
(E) Transgene mRNA expression of AAV8 and Anc80L65 in NHP caudal, right, left, and middle liver lobes by TaqMan probe-specific qRT-PCR. Protein levels are
not available due to lacking antibody and rhCG standards. Quantitation of rhCG transcript is normalized with endogenous GAPDH mRNA levels.intraperitoneal (maximum dose tested [mdt]: 3.9 3 1010 GCs/
mouse), retro-orbital vein injection (mdt: 5 3 1011 GCs/mouse),
subretinal (mdt: 2 3 109 GCs/eye), intravitreal (mdt: 2 3 109
GCs/eye), and direct intramuscular (mdt: 1010 GCs/mouse)Cellwere not observed to have overt toxicity. A more direct assess-
ment was performed in a high-dose intravenous injection of 5 3
1011 GCs/mouse (equivalent to 2 3 1013 GC/kg) of An-
c80L65.TBG.eGFP alongside the following controls: (1) AAV8Reports 12, 1056–1068, August 11, 2015 ª2015 The Authors 1061
Figure 5. Immunological Characterization of Anc80L65
(A) Rabbit anti-AAV serum cross-reactivity. Rabbit antiserum raised against AAV serotypes (y axis) was tested for NAB to Anc80L65 (gray bars) versus the
homologous AAV serotype (black bars) in order to assess relative sero-cross-reactivity. Values (x axis) represent highest dilution at which >50% neutralization is
achieved. Phylogenetic relationship between immunizing serotypes is depicted schematically on the left.
(B) Mouse in vivo gene transfer cross-neutralization. C57Bl/6 mice received an intravenous injection of AAV8 or Anc80L65.CASI.EGFP.2A.A1AT 25 days following
an intramuscular injection with either saline or AAV8.TBG.nLacZ. 14 days following the second injections serumwas titrated by ELISA for hA1AT expression. The
table presents the relative hA1AT levels of the pre-immunized mice versus the non-immunized for each vector (% control) and the NAB titer dilutions for AAV8
(NAB8) and Anc80L65 (NAB80) 24 hr prior to the second injection in the immunized group (n = 5).
(C) A non-structural multiple sequence alignment among Anc80, Anc126, Anc127, and AAV2 VP3 sequences was generated using the T-coffee alignment
package. AAV2 trimer structure was generated using UCSF Chimera. The blue residues represent residues different fromAnc80. The orange residues are defined
T and B cell epitopes on AAV2 (Gurda et al., 2013; Mingozzi et al., 2007). Green residues show the overlap between orange and blue residues to highlight mapped
epitopes altered in the putative evolutionary intermediates. Human T cell epitopes with major histocompatibility complex haplotype: VPQYGYLTL (B*0702),
SADNNNSEY (A*0101), YHLNGRDSL (B*1501), and TTSTRTWAL (B*0801). (Mingozzi et al., 2007) Mouse B cell epitopes of defined AAV2 antibody SADNNNS
plus RGNRQ for C37B Fab (Gurda et al., 2013). In italics are the residues within each epitope that are distinct between Anc80L65 and AAV2.with the same transgene cassette and (2) an equal volume saline
injection. Mice were phlebotomized pre-injection, 2 hr, and 1, 3,
7, 14, and 28 days postinjection, and blood was analyzed for cell
blood counts (CBC) and serum chemistry (Chem) (Tables S3 and
S4). CBC/Chem values for Anc80L65 were within normal range
or comparable to controls. Serum from the 2-hr, 24-hr, 3-day,
and 7-day time points were further evaluated for cytokines as
a measure of innate immune response to the vector antigens
by multiplex 23 cytokine analysis (Table S5). Cytokines for
Anc80L65 were overall concordant with those for saline and
AAV8 control serum, and no major cytokine elevations or de-
creases were observed; however, in some instances, they
were moderately outside the ranges set by the saline control
values in a manner that was more apparent for Anc80L65 than
AAV8. Similar analyses were performed on the blood from the1062 Cell Reports 12, 1056–1068, August 11, 2015 ª2015 The Authorhesus studies described in Figures 4D and 4E. Analogous to
the mouse studies, CBC and Chem values did not demonstrate
signs of toxicity related to the AAV8 or Anc80L65 test article
(Tables S6 and S7)
Pre-existing immunity to AAV serotypes is known to block
gene transfer and may put the patient at risk for adversity due
to recall of memory T cells toward vector antigens shared with
the naturally occurring wild-type virus involved in the primary
infection. We used high-titer rabbit antiserum raised against
AAV serotypes 1, 2, 5, 6.2, 8, 9, and rh.32.33. We furthermore
included rh.10, as its sequence is most closely homologous to
Anc80L65, differing in 8.6% of residues. In Figure 5A, sera
were tested for their ability to neutralize Anc80L65 versus the
homologous vector capsid it was raised against. Results demon-
strate no cross-reactivity to the structurally highly divergentrs
AAV5 and rh32.33, while AAV2, 6.2, and 8, presumed descen-
dants of Anc80L65, demonstrated low-level cross-reactivity,
with between 16- and 1,024-fold reduced neutralization com-
pared to the homologous virus. Among Anc80 lineage members,
no cross-reactivity was observed above the limit of sensitivity for
AAV9 and rh.10. Next, we aimed at validating these results in an
in vivo model for neutralization by pre-immunizing animals for
AAV8 via intramuscular route and, 25 days following the immuni-
zation, assessing the neutralization of Anc80L65 following intra-
venous injection in comparison to AAV8 (Figure 5B). Neutraliza-
tion was complete for AAV8 in the AAV8 pre-immunized animals.
Anc80L65 was neutralized in 2/5 animals, yet demonstrated be-
tween 60%–117% of transduction in three out of five animals
notwithstanding demonstrated AAV8 NAB in those animals.
These results demonstrate partial cross-reactivity of Anc80L65
with AAV8 in rabbit and mouse.
AAV Lineage Analysis and Reconstruction
Strengthened by the successful synthesis of Anc80L65 based on
ASR and its demonstration as a producible, stable, and highly in-
fectious agent for gene therapy, we aimed at providing additional
validation of our approach and modeling methodology by recon-
structing the lineage of AAV further. Our ambition generating this
additional set of reagents was to provide structural intermediates
of phenotypically distinct AAVs permitting empirical evaluation of
the structure-function relationship within this viral family and
highlighting important epistatic couplings informative to future
AAV rational design approaches. A total of eight additional evolu-
tionary intermediates of AAV were reconstructed by ASR and
synthesized in the laboratory (Figure 1): Anc81, Anc82, Anc83,
Anc84, Anc110, and Anc113 were resolved in the branching
leading toward AAV7, 8, and/or 9, while Anc126 and Anc127
are positioned in the natural history of AAV1, 2, and/or 3. For
each of these, the sequence was determined by selecting the
amino acid with highest posterior probability per position (Fig-
ure S2). First, we determined GC viral vector yields following
HEK293 standard triple transfection by TaqMan qPCR. Results
(shown in Figure 6A) demonstrate increased productivity from
Anc80 as the putative ancestor in the AAV7–9 lineage, in line
with the higher production yields of those serotypes such as
AAV8. The AAV1–3 branch did not present yield increases, and
a very poor particle yield was observed for Anc126. It is possible
that Anc126 yields can be improved upon through leveraging the
statistical space, as was the case for Anc80. However, it is
equally likely that Anc126 ASR is less informed due to under-
sampling of this branch of the AAV phylogeny. We further tested
infectivity of the produced particles at equal particle doses
in vitro on HEK293 by GFP and luciferase. All newly synthesized
Anc vectors demonstrated infectivity, although at varying de-
grees (Figure 6B). In the AAV7, 8, and 9 lineage, infectious titers
were overall depressed and more similar to the AAV8 phenotype
than that of Anc80. Anc127, the only intermediate in the Anc80 to
AAV2 lineage that could be tested at equal dose, demonstrated
declined transduction efficiency as compared to both Anc80 and
AAV2. We further tested the heat-stability profile of selected
evolutionary intermediates in both branches of this lineage (Fig-
ure 6C). Interestingly, Anc81 and Anc82 demonstrated high yet
moderately decreased melting temperature in a thermostabilityCellassay compared to Anc80L65, suggesting over time a gradual
reduction of particle denaturation temperature in this branch.
In contrast, Anc127 demonstrated an even further increase
from the already highly thermostable Anc80L65 vector.
Lastly, we explored the ability of ASR to disrupt known epi-
topes to AAV2. Only few B or T cell epitopes have been mapped
on AAV2 to date, all of which were mapped onto Anc80L65,
Anc126, Anc127, and AAV2, representing the AAV2 lineage.
The introduction of the sequential mutations between these
putative evolutionary intermediates highlights in Figure 5C the
overlap between the mutations and two out of four human
T cell epitopes (Mingozzi et al., 2007) and two out of two mouse
B cell epitopes (Gurda et al., 2012). These data highlight the po-
tential of ASR to be used as a method to eliminate or modulate
antigenic regions onto the AAV capsid and may suggest immu-
nity was amajor selective pressure in the natural history of AAVs.
DISCUSSION
Forward genetics studies onmultimeric complex protein assem-
blies are intricately difficult due to the structural constraints
imposed by secondary, tertiary, and quaternary interactions
within and between monomers. Many viruses form icosahedral
capsids as an economical way to build larger complex shells
from smaller repeat units without expending excessive genetic
bandwidth. These 20-faceted structures are composed of 60
subunits (or multiples thereof), each of which can integrate one
or more structural viral proteins. As a function of its triangulation
number andmonomer size, Parvoviridae, with AAV as amember,
are therefore one of the smallest known viruses, with a capsid
diameter in the 18-nm to 26-nm range (Knipe and Howley,
2013). In order for the virus to evolutionary maintain the benefits
from this icosahedral structure, sequence permutations are iter-
atively evaluated, not unlike traditional forward genetic struc-
ture-function experimentation in a laboratory setting. Only those
monomer conformations that efficiently integrate in the icosahe-
dral structure and can provide a selective advantage are able to
persist, ultimately driving speciation. We sought to investigate,
reconstruct, and learn from this natural experimentation using
the simplest of all icosahedral viruses, AAV, as a model.
Here, we aimed at reconstructing the viral lineage of AAV, a
commonly used virus for gene transfer through methodologies
similar to Gullberg et al.’s reconstruction of Coxsackievirus puta-
tive ancestor (Gullberg et al., 2010). First, putative ancestral se-
quences of the AAV capsid protein was inferred using in silico
phylogenetic and statistical modeling. Next, these sequences
were synthesized de novo, and using a traditional virological
technique, the virions derived were evaluated for assembly and
infectivity. We anticipated the solution space containing mono-
mers that structurally integrate into a viral particle and result in
infectious virions to be minimally small, given that the limited
knowledge base on intra- and intermolecular epistasis or the
minimal structural components of AAV that constitute infectivity
or function. To hedge for this anticipated low probability of suc-
cess, ML statistics were used to inform us; we generated a prob-
abilistic sequence space providing margins to account for the
ambiguity of the heuristics used. Screening of the vector library
that emerged from this sequence space yielded Anc80L65, aReports 12, 1056–1068, August 11, 2015 ª2015 The Authors 1063
Figure 6. AAV Lineage Reconstruction Modulates Production, Infectivity, and Thermostability
(A) Production of nine ancestral and two extant viral vectors containing a luciferase reporter gene driven by a CMV promoter determined by qPCR. Error bars
represent SD of three biological replicates.
(B) Ancestral and extant viral vectors were used to transduce HEK293 cells at a particle to cell ratio of 1.93 103. Error bars represent SD of three distinct lots of
vector. *Anc126was added at ratios between 2.13 102 and 3.53 102 GCs/cell due to low vector yield. Gray diverging arrows in (A) and (B) schematically illustrate
AAV2 and AAV8 lineage phenotypic evolution.
(C) Sypro orange thermostability assay indicating denaturation temperatures of selected ancestral and extant AAV vectors. See also Figure S2.viral-like and AAV-like particle, via structural and biochemical
measures (Figures 2 and 3) and 8.6% or 64 amino acids diver-
gent from the closest known AAV sequence. Anc80L65 further-
more demonstrates high stability, unlike any of the tested extant
descendants. Anc80L65 is infectious (Figure 6B), and it is effi-
cient as a gene transfer vehicle in murine models for retina, liver,
and muscle targeting and in non-human primates for liver-
directed gene transfer (Figure 4). Its utility as a gene transfer vec-
tor was further evaluated in a set of safety studies that did not
illustrate vector-related toxicity concerns (Tables S1–S7).
An important property of a gene transfer vector for clinical util-
ity is its ability to be produced efficiently. Vector yields are a
function of the production system and innate structural assembly1064 Cell Reports 12, 1056–1068, August 11, 2015 ª2015 The Authoefficiencies. Anc80L65, exceeding our expectation, yields GCs
in approximately equivalent ranges to AAV2, the most studied
clinical AAV technology to date. AAV2 is reduced compared to
other high-yielding AAVs (Figure 6A). In an attempt to understand
the variation in particle yield, we tested the hypothesis that this
is due to reduced stability. In contrast, Anc80L65 was thermo-
stable up to temperatures of 92C, compared to 68 and 72C
for AAV2 and 8. It is possible that this high thermostability
suggests that a higher activation energy threshold is needed
for Anc80L65 to dissociate and, possibly inversely, assemble.
Further work is required to investigate this fascinating relation-
ship. Another possibility relates to what can be referred to as
the ‘‘Back to the Future’’ concern; here, we present data on anrs
attempt to take the ancestral state of a single virion component
and bring it to life in an otherwise fully contemporary context.
This process conceptually ignores the possibility that co-evolu-
tion took place with other AAV components (e.g., AAP, ITR),
helper functions provided by adenovirus or other helper virus
functions, and the host cell. If indeed such co-evolution
occurred, then those heterologous ancestral components may
be required to bring full functionality to Anc80L65 or any ances-
tral AAV capsomer. To date, no data are available to suggest
such a missing ancestral link is prohibiting further potentiation
of Anc80L65 in its assembly, packaging, or transduction biology.
Building on the validation that Anc80L65 brought to our meth-
odology, we expanded the set of evolutionary intermediates
for experimentation to eight additional Anc particles along the
lineage toward AAV1–3 and 7–9 (Figure 1). We demonstrate as-
sembly, packaging, and in vitro infectivity of these particles.
Particularly along the AAV8 branching from Anc80L65, our
data suggest an increased productivity of viral yields illustrating
that close putative descendants of Anc80L65 were able to over-
come the production limitation discussed above (Figure 6).
In addition to ASR providing a novel methodology to syntheti-
cally derive viral vectors with novel biology, as demonstrated for
Anc80L65, theavailability of functional intermediates of divergent
extant virusesmay enable the elucidation of relevant questions to
the unique biology of the distinct AAV serotypes. In turn, these
data may ultimately make possible structure-guided design of
AAV and tailor it to the specific requirement of a clinical applica-
tion. Our approach may furthermore shed light on the evolu-
tionary pressures of AAV along its modeled natural history. One
such presumed evolutionary pressure is of highest concern for
gene therapy applications. Given that AAV is widely circulating
in humans, long-lived memory T and B cell responses pose a
problem for gene therapy across broad populations. Indeed, in-
dividuals with pre-existing immunity (PEI) to AAV (over 50% in
some populations) are currently excluded from participating in
many AAV clinical trials, as no adequate alternative mitigation
strategies exist to address the problem (Louis Jeune et al.,
2013). Here, we demonstrate that ASR is able tomodulate known
epitopes that govern B and T cell PEI to novel antigenic sites and
thereby possibly reduce the affinity of MHCI-TCR and virus-NAB
interactions (Figure 5). Unlike rabbit vaccination experiments as
in Figure 5A, human PEI is highly cross-reactive across many
serotypes, making it difficult for any AAV-like particle escape
this wide breadth PEI in humans (Brantly et al., 2009; Calcedo
et al., 2009). To evaluate seroprevalence of Anc vectors and
how these data inform a gene therapy outcome, a more robust
and predictive assay is required as are extensive seroprevalence
studies. Indeed, our data highlight traditional NAB assays
poorly correlating with in vivo neutralization (Figures 4D and
5B), as was previously noted (Wang et al., 2010).
In conclusion, ASR is shown to be a powerful methodology
to generate functional intermediates of complex and structur-
ally constrained biological assemblies, here exemplified for
an icosahedral virus, AAV. The ancestral reconstruction of
Anc80L65, the common putative ancestor of AAV1–3 and 7–9,
yielded a highly potent vector particle with potential use in
gene therapy applications via in silico and synthetic biology
methods. The resolution of the lineage from Anc80 toward theseCellextant serotypes provides a toolset of gene transfer reagents
that further can help elucidate complex structure-function rela-
tionships within AAVs and eventually may facilitate structure-
based design of this potential new class of genetic drugs.
EXPERIMENTAL PROCEDURES
Ancestral Sequence Reconstruction of AAV Capsids
These studies were conducted following approval of the Harvard Medical
School Institutional Biosafety Committee (Committee on Microbiological
Safety), which included considerations of dual use of the vector reagents
described here. Ancestral capsid sequences were reconstructed using
maximum-likelihood methods as in Finnigan et al. (2012). An alignment of 75
AAV capsids (GenBank accession numbers in the Supplemental Experimental
Procedures) was generated using PRANK v.121002 using the F option (Lo¨y-
tynoja and Goldman, 2005, 2008) and the JTT+F+G model was determined to
be the phylogenetic model of best fit through the Aikake Information Criterion
as implemented in ProtTest3 (Darriba et al., 2011). The alignment and best-fit
model were then used to infer a phylogeny through PhyML 3.0 (Guindon et al.,
2010), which was evaluated through the approximate likelihood-ratio test
(aLRT) (Anisimova and Gascuel, 2006) as implemented in PhyML. Ancestral
capsid sequences were then inferred with PAML 4.6 (Yang, 2007) through
the Lazarus package developed by the Thornton group.
In order to compensate for the uncertainty inherent to the reconstruction, a
script was written to assess the computed posterior probabilities to identify
ambiguously reconstructed sites. Positionswere considered ambiguous along
the reconstructed capsid sequence if more than one amino acid had a poste-
rior probability greater than 0.3. Eleven such sites were identified on Anc80,
each with two probable amino acids. These 11 dimorphic sites were then
incorporated into a DNA library using the codons from a modern virus
(rh.10). Because the reconstruction did not consider the coevolution of AAP
and the capsid, the AAP open-reading frame (ORF) was ablated by changing
the non-canonical CTG start codon to CAG during library design. In addition,
another downstream ATG also in the AAP ORF was ablated by changing the
codon to AAG. These modifications did not alter the amino acids in the cap
ORF. The DNA library was then synthesized by DNA2.0 and subsequently
subcloned into expression vectors via restriction enzyme digest and ligation.
In Vitro Characterization of AAV Ancestral Lineage Vectors
To identify and characterize functional AAV capsids within Anc80Lib, individual
clones from the subcloned DNA library were isolated and used to produce
luciferase-containing vector in 6 or 96 wells with AAP2 provided in trans. Crude
vector was isolated by filtering cell lysate through a 0.4-mmfilter after 48 hr had
elapsed since transfection. Next, equal volumes of this crude vector prepara-
tion were added to 96-well plates confluent with HEK293 cells, which were
evaluated for their luciferase activity an additional 48 hr later. In total, 776
clones were evaluated. Crude preparations of vector containing a cytomega-
lovirus-driven luciferase were produced by triple transfection in a six-well
format, supplementing AAP in trans to ancestral AAV vectors. In total,
three different independent biological replicates were produced per vector.
DNase-I-resistant transgenes were quantified as above. These crude prepara-
tions of virus were each then evaluated for their ability to transduce HEK293
cells in technical triplicates at an MOI of 1.9E3 GCs/cell with the exception
of Anc126, whichwas added atMOIs between 2.1E2 and 3.5E2GCs/cell. After
48 hr had elapsed, the transduced cells were assessed for luciferase via lumi-
nescence assay.
AAV Vector Preparation
Large-scale polyethylenimine transfections of AAV cis, AAV trans, and adeno-
virus helper plasmid were performed in a ten-layer hyperflask (Corning) with
near-confluent monolayers of HEK293 cells. Plasmids were transfected at a
ratio of 2:1:1 (260 mg of adenovirus helper plasmid/130 mg of cis plasmid/
130 mg of trans plasmid). Transfections for production of Anc vectors were
supplemented with pAAP2 in amounts equivalent to the AAV cis plasmid.
PEI Max (Polysciences)/DNA ratio was maintained at 1.375:1 (w/w). The trans-
fection and downstream purification process were performed as previouslyReports 12, 1056–1068, August 11, 2015 ª2015 The Authors 1065
described (Lock et al., 2010). DNase-I-resistant vector genomes copies were
used to titrate AAV preparations by TaqMan qPCR amplification (Applied Bio-
systems 7500, Life Technologies) with primers and probes detecting pro-
moter, transgene, or poly-adenylation signal coding regions of the transgene
cassette. The purity of the large-scale preparations was evaluated by SDS-
PAGE gel electrophoresis.
In Vivo Gene Transfer
Mouse
C57BL/6 male mice (6–8 weeks old) were purchased from Charles River Lab-
oratories and kept at the Schepens Eye Research Institute (SERI) Animal Facil-
ity. All animal procedures were performed in accordance with protocols
approved by the institutional animal care and use committees at SERI.
For liver-directed studies, male C57BL/6 mice were each injected retro-or-
bitally (150 ml) or intraperitoneally (100 ml). Blood was collected via subman-
dibular bleeds using GoldenRod animal lancets (MEDIpoint). Animals were
euthanized, and livers were collected. Expression of lacZ was assessed using
a b-galactosidase staining kit (Life Technologies, catalog no. K1465-01). In
skeletal muscle studies, male C57BL/6 mice were injected into the rear-right
gastrocnemius muscle (50 ml). Retinal studies were performed by subretinal
injection of male C57BL/6 mice (2 ml).
Non-human Primate
Experiments with rhesus monkeys were performed at New England Primate
Research Center (NEPRC). All experimental procedures were approved by
the Office for Research Subject Protection, Harvard Medical Area Standing
Committee on Animals, the Harvard Medical School Institutional Animal
Care and Use Committee. Animals were sedated with ketamine or telazol in
combination with dexdomitor. AAV was administered intravenously via the
saphenous vein in a 20 ml volume at an approximate rate of 1 ml/min. After
recovering from the injection, the animals were monitored clinically for general
well-being and followed for 2 months. During this time, phlebotomies were
performed at regular intervals to evaluate immune response to AAV and
toxicity. After 70 days, monkeys were euthanized and liver samples were har-
vested. Tissue was harvested in RNALater (Life Technologies).
Additional details are provided in the Supplemental Experimental
Procedures.
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